UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL

被引：0
|
作者：
Rougier, P. [1 ]
Janciauskiene, R. [2 ]
Paramonov, V [3 ]
Shparyk, Y. [4 ]
Gustavsson, B. [5 ]
Wagnerova, M. [6 ]
Gorbunova, V [7 ]
Utracka-Hutka, B. [8 ]
Celik, I [9 ]
Van Cutsem, E. [10 ]
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Kauno Med Univ Klin, Kaunas, Lithuania
[3] Cherkassy Oblasnoy Onkodispanser, Charkassy, Ukraine
[4] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[5] Sahlgrens Univ Hosp, Gothenburg, Sweden
[6] Vychodoslovensky Onkol Ustav, Kosice, Slovakia
[7] RAMN, NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[8] MSC Mem Canc Ctr, Gliwice, Poland
[9] Merck KGaA, Darmstadt, Germany
[10] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [21] KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB
    Van Cutsem, E.
    Lang, I.
    D'Haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Nippgen, J.
    Stroh, C.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 44 - 45
  • [22] Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
    Elez, Elena
    Auxiliadora Gomez-Espana, Maria
    Gravalos, Cristina
    Garcia-Alfonso, Pilar
    Jose Ortiz-Morales, Maria
    Losa, Ferran
    Ales Diaz, Inmaculada
    Grana, Begona
    Toledano-Fonseca, Marta
    Valladares-Ayerbes, Manuel
    Polo, Eduardo
    Salgado, Mercedes
    Martinez de Castro, Eva
    Jose Safont, Maria
    Salud, Antonieta
    Ruiz-Casado, Ana
    Tabernero, Josep
    del Carmen Riesco, Maria
    Rodriguez-Ariza, Antonio
    Aranda, Enrique
    BRITISH JOURNAL OF CANCER, 2022, 126 (06) : 874 - 880
  • [23] ASSOCIATION BETWEEN CPG ISLAND METHYLATOR PHENOTYPE (CIMP) AND TREATMENT RESPONSE OF FOLFIRI WITH CETUXIMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Kim, S. H.
    Park, K. H.
    Shin, S. J.
    Lee, K. Y.
    Kim, T. I.
    Kim, N. K.
    Rha, S. Y.
    Roh, J. K.
    Ahn, J. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 41 - 42
  • [24] RELATIONSHIP BETWEEN KRAS STATUS AND EFFICACY OF FOLFOX6+CETUXIMAB OR FOLFIRI plus CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): THE CECOG/CORE1.2.001 TRIAL
    Ocvirk, J.
    Vrbanec, D.
    Beslija, S.
    Koza, I
    Ciuleanu, T.
    Papamichael, D.
    Wrba, F.
    Messinger, D.
    Zielinski, C.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2009, 20 : 17 - 17
  • [25] The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri
    Van Cutsem, E.
    Lang, I
    D'haens, G.
    Moiseyenko, V
    Zaluski, J.
    Koehne, C.
    Folprecht, G.
    Tejpar, S.
    Shparyk, Y.
    Schlichting, M.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 18
  • [26] ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress
    Wainberg, Z.
    Wang, L.
    Yue, H.
    Motwani, M.
    Kasichayanula, S.
    Blaney, M.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    Gravalos, C.
    Rivera, F.
    Massuti, B.
    Sastre, J.
    Marcuello, E.
    Valladares, M.
    Gil, S.
    Abad, A.
    Diaz-Rubio, E.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Cetuximab plus Xeliri versus cetuximab plus xelox as first-line treatment of patients with metastatic colorectal cancer (MCRC): A randomised trial of the German Aid CRC study group
    Heinernann, V
    Fischer, Von Weikersthal L.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 13 - 13
  • [29] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results
    Yee, L.
    Burris, H. A.
    Kozloff, M.
    Wainberg, Z.
    Pao, M.
    Skettino, S.
    Novotny, W.
    Durbin, B.
    Weston, J.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345